Abstract
Introduction: Benign adult familial myoclonus epilepsy (BAFME) is an autosomal dominant disorder characterized by adult-onset cortical tremor and infrequent generalized seizures. Treatment options for managing involuntary movements in BAFME remain limited. Case Presentation: Here, we present 2 cases involving individuals with BAFME who underwent Vim thalamotomy for tremor-like myoclonus. Despite the intervention, neither patient experienced any improvement in their symptoms. Conclusion: These findings suggest that the Vim may not contribute to the pathophysiology of tremor-like myoclonus in BAFME, despite the established efficacy of Vim thalamotomy in the treatment of essential tremor.
References
1.
Berkovic
SF
, Striano
P
, Tsuji
S
. History of familial adult myoclonus epilepsy/benign adult familial myoclonic epilepsy around the world
. Epilepsia
. 2023
;64
(Suppl 1
):S3
–8
. 2.
Peters
L
, Depienne
C
, Klebe
S
. Familial adult myoclonic epilepsy (FAME): clinical features, molecular characteristics, pathophysiological aspects and diagnostic work-up
. Med Genet
. 2021
;33
(4
):311
–8
. 3.
Wang
G
, Song
Y
, Su
J
, Fan
Z
, Xu
L
, Fang
P
, et al. Altered cerebellar-motor loop in benign adult familial myoclonic epilepsy type 1: the structural basis of cortical tremor
. Epilepsia
. 2022
;63
(12
):3192
–203
. 4.
Schuurman
PR
, Bosch
DA
, Bossuyt
PM
, Bonsel
GJ
, van Someren
EJ
, de Bie
RM
, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor
. N Engl J Med
. 2000
;342
(7
):461
–8
. 5.
Horisawa
S
, Nonaka
T
, Kohara
K
, Mochizuki
T
, Kawamata
T
, Taira
T
. Bilateral radiofrequency ventral intermediate thalamotomy for essential tremor
. Stereotact Funct Neurosurg
. 2023
;101
(1
):30
–40
. 6.
Dallapiazza
RF
, Lee
DJ
, De Vloo
P
, Fomenko
A
, Hamani
C
, Hodaie
M
, et al. Outcomes from stereotactic surgery for essential tremor
. J Neurol Neurosurg Psychiatry
. 2019
;90
(4
):474
–82
. 7.
Kuncel
AM
, Turner
DA
, Ozelius
LJ
, Greene
PE
, Grill
WM
, Stacy
MA
. Myoclonus and tremor response to thalamic deep brain stimulation parameters in a patient with inherited myoclonus-dystonia syndrome
. Clin Neurol Neurosurg
. 2009
;111
(3
):303
–6
. 8.
Wang
JW
, Li
JP
, Wang
YP
, Zhang
XH
, Zhang
YQ
. Deep brain stimulation for myoclonus-dystonia syndrome with double mutations in DYT1 and DYT11
. Sci Rep
. 2017
;7
:41042
. 9.
Asahi
T
, Kashiwazaki
D
, Dougu
N
, Oyama
G
, Takashima
S
, Tanaka
K
, et al. Alleviation of myoclonus after bilateral pallidal deep brain stimulation for Lance-Adams syndrome
. J Neurol
. 2015
;262
(6
):1581
–3
. 10.
Ramdhani
RA
, Frucht
SJ
, Kopell
BH
. Improvement of post-hypoxic myoclonus with bilateral pallidal deep brain stimulation: a case report and review of the literature
. Tremor Other Hyperkinet Mov
. 2017
;7
:461
. 11.
Kobayashi
K
, Katayama
Y
, Otaka
T
, Obuchi
T
, Kano
T
, Nagaoka
T
, et al. Thalamic deep brain stimulation for the treatment of action myoclonus caused by perinatal anoxia
. Stereotact Funct Neurosurg
. 2010
;88
(4
):259
–63
. 12.
Wille
C
, Steinhoff
BJ
, Altenmüller
DM
, Staack
AM
, Bilic
S
, Nikkhah
G
, et al. Chronic high-frequency deep-brain stimulation in progressive myoclonic epilepsy in adulthood: report of five cases
. Epilepsia
. 2011
;52
(3
):489
–96
. 13.
Di Giacopo
A
, Baumann
CR
, Kurthen
M
, Capecchi
F
, Sürücü
O
, Imbach
LL
. Selective deep brain stimulation in the substantia nigra reduces myoclonus in progressive myoclonic epilepsy: a novel observation and short review of the literature
. Epileptic Disord
. 2019
;21
(3
):283
–8
. 14.
Anderson
DG
, Németh
AH
, Fawcett
KA
, Sims
D
, Miller
J
, Krause
A
. Deep brain stimulation in three related cases of North Sea progressive myoclonic epilepsy from South Africa
. Mov Disord Clin Pract
. 2017
;4
(2
):249
–53
. 15.
Horisawa
S
, Miyao
S
, Hori
T
, Kohara
K
, Kawamata
T
, Taira
T
. Comorbid seizure reduction after pallidothalamic tractotomy for movement disorders: revival of Jinnai’s Forel-H-tomy
. Epilepsia Open
. 2021
;6
(1
):225
–9
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
